# Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia

> **NCT00258271** · PHASE1 · COMPLETED · sponsor: **University of Rochester** · enrollment: 18 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** cladribine
- **DRUG:** cytarabine
- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00258271
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2013-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258271, "Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00258271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*